The 36-month beta value for TERN is also noteworthy at -0.38. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for TERN is 62.28M, and at present, short sellers hold a 8.65% of that float. The average trading volume of TERN on December 18, 2024 was 1.53M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TERN) stock’s latest price update
Terns Pharmaceuticals Inc (NASDAQ: TERN)’s stock price has plunge by -5.37relation to previous closing price of 6.80. Nevertheless, the company has seen a -3.96% plunge in its stock price over the last five trading sessions. marketwatch.com reported 2024-12-04 that The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.
TERN’s Market Performance
TERN’s stock has fallen by -3.96% in the past week, with a monthly rise of 12.89% and a quarterly drop of -35.91%. The volatility ratio for the week is 6.20% while the volatility levels for the last 30 days are 7.12% for Terns Pharmaceuticals Inc The simple moving average for the last 20 days is 0.80% for TERN stock, with a simple moving average of -8.90% for the last 200 days.
Analysts’ Opinion of TERN
Many brokerage firms have already submitted their reports for TERN stocks, with Oppenheimer repeating the rating for TERN by listing it as a “Outperform.” The predicted price for TERN in the upcoming period, according to Oppenheimer is $82 based on the research report published on October 31, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see TERN reach a price target of $16. The rating they have provided for TERN stocks is “Buy” according to the report published on June 22nd, 2023.
Jefferies gave a rating of “Buy” to TERN, setting the target price at $18 in the report published on June 07th of the previous year.
TERN Trading at -5.16% from the 50-Day Moving Average
After a stumble in the market that brought TERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.56% of loss for the given period.
Volatility was left at 7.12%, however, over the last 30 days, the volatility rate increased by 6.20%, as shares surge +8.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.67% lower at present.
During the last 5 trading sessions, TERN fell by -4.03%, which changed the moving average for the period of 200-days by -11.80% in comparison to the 20-day moving average, which settled at $6.38. In addition, Terns Pharmaceuticals Inc saw -0.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TERN starting from Burroughs Amy L., who purchase 15,450 shares at the price of $7.15 back on Dec 05 ’24. After this action, Burroughs Amy L. now owns 19,099 shares of Terns Pharmaceuticals Inc, valued at $110,468 using the latest closing price.
Lu Hongbo, the Director of Terns Pharmaceuticals Inc, purchase 476,190 shares at $10.50 during a trade that took place back on Sep 12 ’24, which means that Lu Hongbo is holding 476,190 shares at $4,999,995 based on the most recent closing price.
Stock Fundamentals for TERN
Current profitability levels for the company are sitting at:
- -75.63 for the present operating margin
- 0.47 for the gross margin
The net margin for Terns Pharmaceuticals Inc stands at -66.62. The total capital return value is set at -0.27. Equity return is now at value -28.28, with -27.10 for asset returns.
Currently, EBITDA for the company is -102.56 million with net debt to EBITDA at 2.71. When we switch over and look at the enterprise to sales, we see a ratio of 202.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 32.99.
Conclusion
In summary, Terns Pharmaceuticals Inc (TERN) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
